Insider · CIK 0001574579
Dawn Svoronos
director
Files at ADVM (Adverum Biotechnologies, Inc.), XENE (Xenon Pharmaceuticals Inc.), SLRN (ACELYRIN, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Common Shares | +5,144 | $8.15 | $42k | 31,373 | 39 d ago |
| Sep 1, 2026 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Stock Option (Right to Buy)derivative | -5,144 | $0.00 | $0 | 0 | 39 d ago |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | UTender of shares Common Stock | -5,000 | - | - | 0 | Dec 10, 2025 |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,500 | - | - | 0 | Dec 10, 2025 |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,000 | - | - | 0 | Dec 10, 2025 |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,000 | - | - | 0 | Dec 10, 2025 |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,000 | - | - | 0 | Dec 10, 2025 |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,520 | - | - | 0 | Dec 10, 2025 |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,450 | - | - | 0 | Dec 10, 2025 |
| Jun 17, 2025 | ADVM Adverum Biotechnologies, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +10,450 | $0.00 | $0 | 10,450 | Jun 20, 2025 |
| Jun 5, 2025 | XENE Xenon Pharmaceuticals Inc. | AGrant or award Share Option (Right to Buy)derivative | +17,012 | $0.00 | $0 | 17,012 | Jun 6, 2025 |
| Jun 5, 2025 | XENE Xenon Pharmaceuticals Inc. | AGrant or award Restricted Share Unitsderivative | +2,645 | $0.00 | $0 | 2,645 | Jun 6, 2025 |
| May 21, 2025 | SLRN ACELYRIN, Inc. | DDisposition to issuer Common Stock | -15,000 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | SLRN ACELYRIN, Inc. | DDisposition to issuer Director Stock Option (right to buy)derivative | -92,158 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | SLRN ACELYRIN, Inc. | DDisposition to issuer Director Stock Option (right to buy)derivative | -23,243 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | SLRN ACELYRIN, Inc. | DDisposition to issuer Director Stock Option (right to buy)derivative | -155,450 | - | - | 0 | May 23, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.